These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24046251)

  • 21. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
    Rodon P; Hulin C; Pegourie B; Tiab M; Anglaret B; Benboubker L; Jardel H; Decaux O; Kolb B; Roussel M; Garderet L; Leleu X; Fitoussi O; Chaleteix C; Casassus P; Lenain P; Royer B; Banos A; Benramdane R; Cony-Makhoul P; Dib M; Fontan J; Stoppa AM; Traullé C; Vilque JP; Pétillon MO; Mathiot C; Dejoie T; Avet-Loiseau H; Moreau P
    Haematologica; 2015 Feb; 100(2):e56-9. PubMed ID: 25398832
    [No Abstract]   [Full Text] [Related]  

  • 23. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
    Romano A; Chiarenza A; Consoli U; Conticello C; Forte S; Uccello G; Vetro C; Cavalli M; Coppolino F; Palumbo GA; Di Raimondo F
    Ann Oncol; 2013 Apr; 24(4):1038-44. PubMed ID: 23136226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine: the remedy that came in from the cold.
    Lentzsch S
    Blood; 2014 Feb; 123(7):948-50. PubMed ID: 24526773
    [No Abstract]   [Full Text] [Related]  

  • 28. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
    Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
    Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
    Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
    Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
    Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
    Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    An N; Li X; Shen M; Chen SL; Huang ZX
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
    Kobayashi T; Kuroda J; Shimura K; Akaogi T; Kawata E; Kiyota M; Tanaka T; Kamitsuji Y; Murakami S; Hatsuse M; Okano A; Iwai T; Ueda S; Koshida M; Uchiyama H; Matsumoto Y; Kaneko H; Uoshima N; Ueda Y; Kobayashi Y; Shimazaki C; Horiike S; Taniwaki M
    Int J Hematol; 2010 Nov; 92(4):579-86. PubMed ID: 20924731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.